{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:33:58Z","timestamp":1768401238658,"version":"3.49.0"},"reference-count":69,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2025.2608811","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:24:39Z","timestamp":1768281879000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged \u226550\u2009years in Canada"],"prefix":"10.1080","volume":"25","author":[{"given":"Peter P.","family":"Mueller","sequence":"first","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Meilleur","sequence":"additional","affiliation":[{"name":"Merck Canada Inc","place":["Kirkland, Quebec, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinan","family":"Yi","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Martino","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwame","family":"Owusu-Edusei","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7203a1"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.824788"},{"issue":"7","key":"e_1_3_6_4_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JCM.00540-21","article-title":"Structural, genetic, and serological elucidation of Serogroup 24 serotypes: discovery of a New serotype, 24C, with a variable capsule structure","volume":"59","author":"Ganaie F","year":"2021","unstructured":"Ganaie F, Maruhn K, Li CX, et al. Structural, genetic, and serological elucidation of Serogroup 24 serotypes: discovery of a New serotype, 24C, with a variable capsule structure. J Clin Microbiol. 2021;59(7):1\u201316. https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00540-21","journal-title":"J Clin Microbiol"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00937-20"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094580"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0001-8"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30310-4"},{"key":"e_1_3_6_9_1","unstructured":"Centers for Disease Control and Prevention. Chapter 11: pneumococcal manual for the surveillance of vaccine-preventable diseases: CDC. 2020 [cited 2023 May]. Available from: https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt11-pneumo.html"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.05.061"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052116"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060273"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy800"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-206780"},{"key":"e_1_3_6_15_1","unstructured":"Public Health Agency of Canada. Surveillance of invasive pneumococcal disease: Canadian notifiable disease surveillance System (CNDSS). Ottawa (ON); 2024 [cited 2024 May 30]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/vaccine-preventable-diseases\/invasive-pneumococcal-disease\/surveillance.html"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v50i05a02"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.02.081"},{"key":"e_1_3_6_18_1","unstructured":"National Advisory Committee on Immunization (NACI). Public health level recommendations on the use of pneumococcal vaccines in adults including the use of 15-valent and 20-valent conjugate vaccines. Ottawa (ON) Canada: NACI; 2023 [cited 2024 May 20]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines.html"},{"key":"e_1_3_6_19_1","unstructured":"Public Health Agency of Canada (PHAC). Canada\u2019s provincial and territorial routine vaccination programs for healthy previously immunized adults (aged 18 years and older). 2015 [cted 2024 Sep 17]. Available from: https:\/\/healthycanadians.gc.ca\/healthy-living-vie-saine\/immunization-immunisation\/children-enfants\/alt\/schedule-calendrier-table-3-eng.pdf"},{"key":"e_1_3_6_20_1","unstructured":"Manitoba routine immunization schedules: Manitoba health. 2024 [cited 2024 Sep 17]. Available from: https:\/\/www.gov.mb.ca\/health\/publichealth\/cdc\/div\/schedules.html"},{"key":"e_1_3_6_21_1","unstructured":"New Brunswick routine immunization schedule: New Brunswick health. 2024 [cited 2024 Sep 17]. Available from: https:\/\/www2.gnb.ca\/content\/gnb\/en\/corporate\/promo\/vaccines-and-immunization\/routine-immunization-schedule.html#4"},{"key":"e_1_3_6_22_1","unstructured":"Injection authority and vaccine administration in pharmacies across Canada: Canadian pharmacists association. 2024 [cited 2024 Sep 17]. Available from: https:\/\/www.pharmacists.ca\/cpha-ca\/assets\/File\/cpha-on-the-issues\/InjectionVaccinationScan_Feb2024_EN.pdf"},{"key":"e_1_3_6_23_1","unstructured":"Merck & Co. Inc. Rahway NJ USA. Safety and immunogenicity of V116 in pneumococcal vaccine-na\u00efve adults (V116-003 STRIDE-3). 2022. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05425732;"},{"key":"e_1_3_6_24_1","unstructured":"CAPVAXIVE\u00ae (pneumococcal 21-valent conjugate vaccine) product monograph: health Canada. 2024 [cited 2024 Sep 17]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00076331.PDF"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.10.029"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-00988-1"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127264"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2025.108159"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2496070"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2445429"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01067-1"},{"key":"e_1_3_6_32_1","unstructured":"Statitics Canada. Consumer price index annual average not seasonally adjusted: statistics Canada. 2024 [cited 2024 Jun 20]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000501"},{"key":"e_1_3_6_33_1","unstructured":"National Advisory Committee on Immunization (NACI). Public health level recommendations on the use of pneumococcal vaccines in adults including the use of 15-valent and 20-valent conjugate vaccines: economic evidence supplementary appendix. Ottawa (ON) Canada: NACI; 2023 [cited 2024 May 20]. Available from: https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-recommendations-public-health-programs-use-pneumococcal-vaccines-children-including-use-15-valent-20-valent-conjugate-vaccines-economic-evidence-supplementary-appendix\/naci-appendix-2024-03-11.pdf"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v48i09a04"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040748"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116770"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.016"},{"key":"e_1_3_6_38_1","volume-title":"Cost-effectiveness analysis of pneumococcal vaccinations among adults in the US","author":"Mathijssen I","year":"2021","unstructured":"Mathijssen I. Cost-effectiveness analysis of pneumococcal vaccinations among adults in the US. Rahway (NJ), USA: Merck Sharp & Dohme LLC; 2021."},{"key":"e_1_3_6_39_1","unstructured":"Averin AM Weycker D Kutrieb E et al. Cost-effectiveness of 20-valent conjugate vaccine in Canadian adults: technical report prepared for Pfizer Canada. Kirkland (QC): Pfizer Canada; 2021."},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408544"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003326"},{"key":"e_1_3_6_42_1","volume-title":"ACIP meeting Pneumococcal Vaccines","author":"Stoecker C","year":"2021","unstructured":"Stoecker C. Economic assessment of PCV15 & PCV20. ACIP meeting Pneumococcal Vaccines; 2021. Available from: https:\/\/www.youtube.com\/watch?v=h3fHBq9Ez1Q"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.049"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.09.019"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.049"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2018.12.007"},{"key":"e_1_3_6_47_1","unstructured":"Qu\u00e9bec Rdlamd. List of vaccines available at pharmacies and covered according to the conditions of the Qu\u00e9bec immunization program. 2024 [cited 2024 Sep 23]. Available from: https:\/\/www.ramq.gouv.qc.ca\/sites\/default\/files\/documents\/non_indexes\/liste-vaccins-2024-09-14-en_0.pdf"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2257426"},{"key":"e_1_3_6_49_1","unstructured":"Alberta population norms for the EQ-5D-5L: the APERSU team. 2018 [cited 2024 Sep 23]. Available from: https:\/\/sites.google.com\/ualberta.ca\/apersu\/about-eq-5d\/eq-5d-population-norms?authuser=0#h.pm2mofsx3vtu"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.05.007"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-011-0360-9"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2302-3"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2808.212469"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ028"},{"key":"e_1_3_6_55_1","unstructured":"Statitics Canada. Population estimates on July 1 by age and gender: statistics Canada. 2024 [cited 2024 Jun 20]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000501"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0508-2"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-3350"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.821"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030127"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03277-3"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.06.007"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.04.002"},{"key":"e_1_3_6_63_1","unstructured":"National advisory committee on immunization. Interpretation guide \u2013 health economics. NACI; 2024 [cited 2024 Sep 17]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/methods-process\/interpretation-guide-health-economics.html"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040748"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01067-1"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126985"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3651-0"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.052"},{"issue":"5","key":"e_1_3_6_69_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.14745\/ccdr.v50i05a02","article-title":"Invasive pneumococcal disease surveillance in Canada, 2021\u20132022","volume":"50","author":"Griffith A","year":"2024","unstructured":"Griffith A, Golden AR, Lefebvre B, et al. Invasive pneumococcal disease surveillance in Canada, 2021\u20132022. Can Commun Dis Rep. 2024 May 24;50(5):121\u2013134.","journal-title":"Can Commun Dis Rep"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00805-5"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2025.2608811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:52:07Z","timestamp":1768380727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2025.2608811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2025.2608811"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2025.2608811","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2608811"}}